Source-grounded facts extracted from Ingevity Corp's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Ryan Cotterman was appointed as Vice President, Chief Accounting Officer and principal accounting officer at Ingevity Corp.
“On June 22, 2026, Ryan Cotterman, age 44, was appointed as Vice President, Chief Accounting Officer and principal accounting officer of Ingevity Corporation (the “Company”).”
Ingevity Corp updated its full year guidance (reaffirmed).
“Reaffirms full year guidance, adjusted for sale of Road Markings”
Ingevity Corp reported three months ended March 31, 2026 results: revenue $258.0 million, net income $23.4 million, EPS $0.65.
“Ingevity reports first quarter 2026 financial results First Quarter 2026 Results & Recent Highlights: • Net sales of $258.0 million increased 4% from prior year • Net income from continuing operations of $23.4 million and $0.65 per diluted share compared to $29.1 million and $0.79 in the prior year”
Ingevity Corp shareholders approved Approval of amendment to increase authorized shares under Ingevity Corporation 2025 Omnibus Incentive Plan.
“Approval of amendment to increase authorized shares under the Ingevity Corporation 2025 Omnibus Incentive Plan. FOR AGAINST ABSTAIN BROKER NON-VOTE 31,038,374 990,650 26,224 1,443,084”
Ingevity Corp shareholders approved Ratification of PricewaterhouseCoopers LLP as independent auditor for fiscal 2026.
“Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for fiscal 2026. FOR AGAINST ABSTAIN BROKER NON-VOTE 33,358,881 118,571 20,880 —”
Ingevity Corp shareholders approved Approval, on a non-binding advisory basis, of named executive officer compensation.
“Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers. FOR AGAINST ABSTAIN BROKER NON-VOTE 28,593,615 3,435,921 25,712 1,443,084”
Ingevity Corp shareholders approved Election of nine director nominees.
“Election of the nine (9) director nominees listed below, each for a one-year term or until his or her successor is duly elected and qualified: FOR WITHHELD Luis Fernandez-Moreno 31,173,836 862,109 Diane H. Gulyas 31,183,123 852,804 Bruce D. Hoechner 31,180,872 855,239 David H. Li 31,939,655 95,708 Frederick J. Lynch 31,776,737 259,113 Karen G. Narwold 31,924,348 119,369 F. David Segal 31,837,299 196,600 J. Kevin Willis 31,941,621 96,426 Benjamin G. (Shon) Wright 31,868,404 167,381”
Ingevity Corp amended revolving credit of decreased from $1 billion to $750 million with JPMorgan Chase Bank, N.A. at term benchmark rate (subject to 0.00% floor) plus applicable margin of 1.00% to maturing five years after the Closing Date (March 26, 2026).
“The Amendment amends and restates the Existing Credit Agreement to, among other things, (a) extend the maturity date of the Company’s revolving credit facility to the date that is five years after the Closing Date, (b) decrease the aggregate amount of the commitments thereunder from $1 billion to $750 million and (c) effect certain other amendments.”
Ingevity Corp entered into Second Amendment and Restatement Agreement with JPMorgan Chase Bank, N.A., as administrative agent valued at $750 million (effective 2026-03-26).
“On March 26, 2026 (the “ Closing Date ”), Ingevity Corporation (the “ Company ”), Ingevity Holdings SRL (“ Holdings ”), Ingevity UK Ltd (the “ UK Borrower ”), the other loan parties party thereto, the lenders party thereto, the issuing banks party thereto and JPMorgan Chase Bank, N.A., as administrative agent (the “ Administrative Agent ”), collateral agent and swingline lender, entered into that certain Second Amendment and Restatement Agreement (the “ Amendment ”), which amends and restates the Amended and Restated Credit Agreement, dated as of June 23, 2022”
Ingevity Corp amended Amendment with the Parties (effective 2026-01-01).
“In connection with the Closing, on January 1, 2026, the Parties entered into the Amendment, which, among other things, modified the scope of assets being transferred pursuant to the Original Purchase Agreement by excluding non-lignin dispersant products sold to existing customers for agricultural chemical applications.”
Ingevity Corp completed a disposition involving Mainstream Pine Products, LLC (closed 2026-01-01).
“On January 1, 2026, Ingevity Corporation, a Delaware corporation (“Ingevity”), completed the transaction (the “Transaction”) previously disclosed in its Current Report on Form 8-K filed by Ingevity with the Securities and Exchange Commission (“SEC”) on September 4, 2025 (the “Previous Form 8-K”).”
Bruce D. Hoechner was elected as Chair of the Board at Ingevity Corp.
“the election of Mr. Bruce D. Hoechner as Chair of the Board”
F. David Segal was elected as Director at Ingevity Corp.
“the election of Mr. David H. Li and Mr. F. David Segal to fill the vacancies created by the expansion of the Board”
David H. Li was elected as Director at Ingevity Corp.
“the election of Mr. David H. Li and Mr. F. David Segal to fill the vacancies created by the expansion of the Board”
Luis Fernandez-Moreno departed as interim President and Chief Executive Officer at Ingevity Corp.
“In connection with Mr. Li’s appointment, Luis Fernandez-Moreno will step down as interim President and Chief Executive Officer of Ingevity as of the Effective Date.”
David H. Li was appointed as President and Chief Executive Officer at Ingevity Corp.
“On March 10, 2025, Ingevity Corporation (“Ingevity”) announced that its Board of Directors (the “Board”) has appointed David H. Li as President and Chief Executive Officer of Ingevity, effective April 7, 2025”
Ingevity Corp: Amended and restated bylaws to revise procedural and disclosure requirements for stockholder nominations and proposals (effective 2024-10-22).
“On October 22, 2024, the Board of Directors of Ingevity Corporation (the “Company”) approved and adopted amended and restated bylaws of the Company (the “Fourth Amended and Restated Bylaws”), which further amend and restate the Company’s previously adopted bylaws.”
Luis Fernandez-Moreno was appointed as interim President and Chief Executive Officer at Ingevity Corp.
“the Board has appointed Luis Fernandez-Moreno as the interim President and Chief Executive Officer of the Company”
John C. Fortson resigned as Member of the Board at Ingevity Corp.
“He succeeds John C. Fortson, who departed as President and Chief Executive Officer and has resigned as a member of the Board, effective as of October 2, 2024.”
John C. Fortson departed as President and Chief Executive Officer at Ingevity Corp.
“He succeeds John C. Fortson, who departed as President and Chief Executive Officer and has resigned as a member of the Board, effective as of October 2, 2024.”
Ingevity Corp announced a restructuring with charges of aggregate charges of approximately $100 million affecting Performance Chemicals segment; Crossett, Arkansas manufacturing plant.
“As a result of these actions, Ingevity expects to incur aggregate charges of approximately $100 million, consisting of approximately $65 million in asset-related charges, approximately $10 million in severance and other employee-related costs and approximately $25 million in other restructuring costs, which include decommissioning, dismantling and removal charges and contract termination costs.”
Ryan C. Fisher was appointed as Senior Vice President, General Counsel and Secretary at Ingevity Corp.
“Ryan C. Fisher, previously the Company’s Vice President, Deputy General Counsel and Chief Compliance Officer, has been appointed Senior Vice President, General Counsel and Secretary of the Company.”
Stacy L. Cozad resigned as Executive Vice President, General Counsel and Secretary at Ingevity Corp.
“On June 26, 2024, Stacy L. Cozad notified Ingevity Corporation (the “Company”) of her decision to resign as Executive Vice President, General Counsel and Secretary of the Company, which resignation took effect as of such date.”
Ingevity Corp reported the three months ended March 31, 2024 results: revenue $340.1 million, net income Net loss of $56.0 million and diluted loss per share (EPS) of $1.54; adjusted earnings of $19.1 million and diluted adju. Guidance reaffirmed.
“John E. Nypaver, Jr. 843-740-2002 investors@ingevity.com Ingevity reports first quarter 2024 financial results HIGHLIGHTS : (comparisons versus prior year period) • Net sales of $340.1 million, down 13% primarily as a result of the repositioning of Performance Chemicals • Net loss of $56.0 million and diluted loss per share (EPS) of $1.54; adjusted earnings of $19.1”
Ingevity Corp shareholders approved Approval of amendment to the Company’s Certificate of Incorporation to provide for the exculpation of certain officers from liability in limited circumstances at the 2024-04-23 meeting.
“Approval of amendment to the Company’s Certificate of Incorporation to provide for the exculpation of certain officers from liability in limited circumstances.”
Ingevity Corp shareholders approved Ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for fiscal 2024 at the 2024-04-23 meeting.
“Ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for fiscal 2024.”
Ingevity Corp shareholders approved Approval, on a non-binding, advisory basis, of the compensation of our named executive officers at the 2024-04-23 meeting.
“Approval, on a non-binding, advisory basis, of the compensation of our named executive officers.”
Ingevity Corp shareholders approved Election of nine director nominees at the 2024-04-23 meeting.
“Election of the nine (9) director nominees listed below, each for a one-year term or until his or her successor is duly elected and qualified:”
William J. Slocum resigned as Director at Ingevity Corp.
“On March 12, 2024, William J. Slocum informed the Nominating & Governance Committee of the Board of Directors (the “Board”) of Ingevity Corporation (the “Company”) of his resignation from the Board effective as of March 13, 2024 at 5:00 p.m.”
Ingevity Corp reported the twelve months ended December 31, 2023 results: revenue $1.69 billion, net income Net loss of $5.4 million and diluted loss per share of $0.15, EPS diluted loss per share of $0.15. Guidance initiated.
“assets to be shut down during the first half of the year • Implemented significant cost savings actions Full Year (comparisons versus prior year period): • Net sales of $1.69 billion increased 1.4% • Net loss of $5.4 million and diluted loss per share of $0.15, including restructuring charges of $145.3 million; adjusted earnings of $144.7 million and diluted”
Ingevity Corp reported the three months ended December 31, 2023 results: revenue $371.7 million, net income Net loss of $116.8 million and diluted loss per share of $3.23, EPS diluted loss per share of $3.23. Guidance initiated.
“843-740-2002 investors@ingevity.com Ingevity reports fourth quarter and full year 2023 financial results Fourth Quarter (comparisons versus prior year period): • Net sales of $371.7 million decreased 3.1% • Net loss of $116.8 million and diluted loss per share of $3.23, including restructuring charges of $107.5 million; adjusted earnings of $7.8 million and diluted”
Ingevity Corp reported the three and nine months ended September 30, 2023 results: revenue $446.0 million, net income $25.2 million, EPS $0.69.
“Ingevity reports third quarter 2023 financial results HIGHLIGHTS : (comparisons versus prior year period) • Net sales of $446.0 million, down 7%, compared to a record prior year • Net income of $25.2 million and diluted earnings per share (EPS) of $0.69”
Ingevity Corp announced a restructuring with charges of approximately $280 million affecting Performance Chemicals segment; DeRidder, Louisiana manufacturing plant.
“the Board of Directors approved the permanent closure of the Company’s Performance Chemicals manufacturing plant located in DeRidder, Louisiana (the “DeRidder Plant”), as well as additional corporate and business cost reduction actions. The Company expects to close the DeRidder Plant by the end of the first half of 2024. The Company expects to incur aggregate charges of approximately $280 million associated with these actions, consisting of approximately $180 million in asset-related charges, approximately $15 million in severance and other employee costs, and approximately $85 million in other restructuring costs including decommissioning, dismantling and removal charges, and contract termination costs.”
Ingevity Corp amended Amendment No.1 with WestRock Shared Services, LLC and WestRock MWV, LLC, on behalf of the affiliates of WestRock Company (effective 2023-11-01).
“On November 1, 2023, Ingevity Corporation (the “Company”), and WestRock Shared Services, LLC and WestRock MWV, LLC, on behalf of the affiliates of WestRock Company (“WestRock”), entered into Amendment No.1 (the “Amendment”) to that certain Amended and Restated Crude Tall Oil and Black Liquor Soap Skimmings Agreement, dated as of March 20, 2023, by and between the Company and WestRock (the “Supply Agreement”).”
Ingevity Corp reported preliminary financial results for three and six months ended June 30, 2023.
“On August 2, 2023, Ingevity Corporation ("Ingevity") announced its preliminary financial results for the three and six months ended June 30, 2023 which are attached as Exhibit 99.1 to this Current Report on Form 8-K.”
Ingevity Corp updated its for the three months ended March 31, 2023 guidance (reaffirmed).
“On May 3, 2023, Ingevity Corporation ("Ingevity") announced its preliminary financial results for the three months ended March 31, 2023”
Ingevity Corp shareholders approved Approval of amendment and restatement of the 2017 Ingevity Corporation Employee Stock Purchase Plan. at the 2023-04-27 meeting.
“5. Approval of amendment and restatement of the 2017 Ingevity Corporation Employee Stock Purchase Plan.”
Ingevity Corp shareholders approved Ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for fiscal 2023. at the 2023-04-27 meeting.
“4. Ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for fiscal 2023.”
Ingevity Corp shareholders approved Approval, on a non-binding basis, of the frequency of named executive officer compensation advisory vote. at the 2023-04-27 meeting.
“3. Approval, on a non-binding basis, of the frequency of named executive officer compensation advisory vote.”
Ingevity Corp shareholders approved Approval, on a non-binding, advisory basis, of the compensation of our named executive officers. at the 2023-04-27 meeting.
“2. Approval, on a non-binding, advisory basis, of the compensation of our named executive officers.”
Ingevity Corp shareholders approved Election of the ten director nominees listed below, each for a one-year term or until his or her successor is duly elected and qualified. at the 2023-04-27 meeting.
“1. Election of the ten (10) director nominees listed below, each for a one-year term or until his or her successor is duly elected and qualified:”
Ingevity Corp amended Georgia-Pacific Supply Amendment with Georgia-Pacific LLC and GP Pine Chemicals LLC (effective 2023-03-21).
“On March 21, 2023, Ingevity, Georgia-Pacific LLC, on behalf of itself and its subsidiaries (“Georgia-Pacific”), and GP Pine Chemicals LLC, a direct subsidiary of Georgia-Pacific LLC (“GP Pine Chemicals”), entered into a Second Amendment to the Crude Tall Oil Supply Agreement (the “Georgia-Pacific Supply Amendment”), to amend certain terms of the Crude Tall Oil Supply Agreement, dated as of March 9, 2018”
Ingevity Corp entered into WestRock Supply Agreement with WestRock Shared Services, LLC and WestRock MWV, LLC (effective 2023-03-20).
“On March 20, 2023, Ingevity Corporation, a Delaware corporation (“Ingevity,” the “Company,” “we,” “us,” or “our”), and WestRock Shared Services, LLC and WestRock MWV, LLC, on behalf of the affiliates of WestRock Company (“WestRock”), entered into an amended and restated crude tall oil and black liquor soap skimmings agreement (the “WestRock Supply Agreement”), which amends and restates that certain crude tall oil and black liquor soap skimmings agreement, dated as of January 1, 2016”
Ingevity Corp reported full year 2023 results: revenue between $1.9 billion and $2.1 billion. Guidance initiated.
“Guidance: Company announces full year 2023 guidance for sales between $1.9 billion and $2.1 billion and adjusted EBITDA between $495 million and $515 million.”
Ingevity Corp reported the twelve months ended December 31, 2022 results: revenue $1.67 billion, net income $211.6 million, EPS $5.50.
“Full Year (comparisons versus prior year period): • Net sales of $1.67 billion increased 19.9% • Net income of $211.6 million and diluted EPS of $5.50”
Ingevity Corp reported the three months ended December 31, 2022 results: revenue $383.6 million, net income $15.6 million, EPS $0.41.
“Fourth Quarter (comparisons versus prior year period): • Net sales of $383.6 million increased 14.2%; • Net income of $15.6 million and diluted earnings per share (EPS) of $0.41”
Bruce D. Hoechner was elected as Director at Ingevity Corp.
“the election of Mr. Bruce D. Hoechner to fill the vacancy created by the expansion of the Board.”
Ingevity Corp reported full year 2022 results: revenue between $1.65 billion and $1.70 billion. Guidance raised.
“Company raises full year 2022 sales guidance to between $1.65 billion and $1.70 billion and adjusted EBITDA to between $460 million and $475 million”
Ingevity Corp reported the three months ended September 30, 2022 results: revenue $482.0 million, net income $75.4 million, EPS $1.98. Guidance raised.
“Ingevity reports third quarter 2022 financial results HIGHLIGHTS : (comparisons versus prior year period) • Company delivered record sales of $482.0 million, up 27.9% • Net income of $75.4 million and diluted earnings per share (EPS) of $1.98;”
Benjamin G. Wright was elected as Director at Ingevity Corp.
“the election of Mr. William J. Slocum and Mr. Benjamin G. (“Shon”) Wright to fill the vacancies relating, in part, to the expansion of the Board.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.